Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of alisertib and TAK-228 that can be given to participants with advanced solid
tumors that are associated with HPV. Researchers also want to learn if the study drug
combination can help to control advanced solid tumors.